Brought to you by 
Actelion acquires Axovan
05 Nov 2003
Executive Summary
Actelion Ltd. (develops drugs that act on the endothelium) has agreed to acquire the 91% of Axovan AG (G protein-coupled receptor drug targets) it did not already own. Axovan is valued at CHF60mm ($45.2mm) and at the time of the agreement had a cash position of $11mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Partial Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actelion acquires Axovan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice